




About Us Sloan Kettering Institute The Michel Sadelain Lab

Research

## Marco L. Davila, MD, PhD

Education & Training Assistant Member



Marco L. Davila 1/3

My research focuses on the development of T cell immunotherapies for hematologic malignancies. We create chimeric antigen receptors, CARs, which are composed of a tumor-antigen-binding domain fused to T-cell-signaling components such as CD28 and CD3zeta. We are able to target CARs to any cell-surface antigen on tumor cells, which supports tumor recognition by the T cell and subsequent killing of the tumor cell. We have generated an animal model for acute leukemia and validated the antitumor efficacy and safety of CD19 CAR-targeted T cells. We are using this preclinical model to evaluate mechanisms for regulation of CAR T cells by the immune system. We are also developing new CARs against other targets of hematologic malignancies. This work has been the foundation for a clinical protocol currently open at Memorial Sloan Kettering for which I am the principal investigator.

- About Us
<u>Overview</u>
Leadership
<u>Administration</u>
<u>History</u>
Contact Us
- Research
<u>Overview</u>
Research programs
Research labs
Core facilities & resources
- Education & Training
<u>Overview</u>
Postdoctoral training
Gerstner Sloan Kettering Graduate School
Joint graduate programs
Programs for college & high school students
- News & Events
<u>Overview</u>
Seminars & events
- Open Positions
<u>Overview</u>

Marco L. Davila 2/3

Faculty positions

Postdoctoral positions

Communication preferences

Cookie preferences

Legal disclaimer

**Accessibility Statement** 

Privacy policy

Public notices

© 2024 Memorial Sloan Kettering Cancer Center

Marco L. Davila 3/3